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Background: Low-dose opioids can relieve breathlessness but may be underused in late-stage 
COPD due to fear of complications, contributing to poor symptom control.
Objectives: We aimed to study the period prevalence and indications of opioids actually 
prescribed in people with end-stage COPD.
Methods: The study was a longitudinal, population-based study of patients starting long-term 
oxygen therapy (LTOT) for COPD between October 1, 2005 and June 30, 2009 in Sweden. 
A random sample (n=2,000) of their dispensed opioid prescriptions was obtained from the national 
Prescribed Drugs Register from 91 days before starting LTOT until the first of LTOT withdrawal, 
death, or study end (December 31, 2009). We analyzed medication type, dispensed quantity, date 
of dispensing, and indications categorized as pain, breathlessness, other, or unknown.
Results: In total, 2,249 COPD patients (59% women) were included. During a median follow-up 
of 1.1 (interquartile range 0.6–2.0) years, 1,034 patients (46%) were dispensed $1 opioid 
prescription (N=13,722 prescriptions). The most frequently prescribed opioids were tramadol 
(23%), oxycodone (23%), morphine (16%), and codeine (16%). Average dispensed quantity was 
9.3 (interquartile range 3.7–16.7) defined daily doses per prescription. In the random sample, 
the most commonly stated indication was pain (97%), with only 2% for breathlessness and 1% 
for other reasons.
Conclusion: Despite evidence that supported the use of opioids for the relief of breathlessness 
predating this study, opioids are rarely prescribed to relieve breathlessness in oxygen-dependent 
COPD, potentially contributing to less-than-optimal symptom control. This study creates a 
baseline against which to compare future changes in morphine prescribing in this setting.
Keywords: COPD, symptoms, breathlessness, opioids, prescriptions, LTOT
Introduction
COPD is a leading cause of mortality worldwide, and is associated with high burden 
of symptoms, often poorly controlled in advanced disease stages.1–4 The prevalence 
and severity of breathlessness are higher in end-stage COPD than in advanced lung 
cancer, both during the final year of life and in the terminal weeks and days near 
death.5,6 Despite long-term oxygen therapy (LTOT), most COPD patients suffer 
from breathlessness at rest or on minimal exertion that greatly limits even the basic 
activities of daily living.7–9 Breathlessness that persists at rest or on minimal exer-
tion despite optimal treatment of the underlying disease(s) is termed “refractory 
breathlessness.”10,11
Opioids have a growing evidence base for decreasing refractory breathlessness 
in advanced COPD.10,12 Jennings et al concluded in a Cochrane meta-analysis that 
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low doses of oral sustained-release morphine can reduce 
chronic refractory breathlessness,12 which was confirmed by 
an adequately powered crossover trial in 2003.10
Clinicians may, however, be reluctant to prescribe opi-
oids due to a fear of adverse events including confusion, 
falls, and respiratory depression in patients with respiratory 
compromise.13 Among stable outpatients with advanced 
COPD, 94% reported moderate to severe breathlessness but 
only 2% used opioids, such as morphine.13 In palliative care, 
only one-fourth of COPD patients received opioids during 
their last 6 months of life, compared to half of the patients 
with lung cancer.14
No study has evaluated the indications for actual 
prescribed opioids, and data are limited on the temporal 
trends and prescription as death approaches. A recent study 
reported that opioid therapy, mostly short-term, was com-
monly used in COPD but did not analyze the indications for 
opioid use.15 Underuse of opioids for breathlessness in severe 
COPD could contribute to insufficient symptom control and 
unnecessary suffering.
The aim of this study was to evaluate the indications, 
medication types, and temporal patterns of opioid prescrip-
tion in severe oxygen-dependent COPD.
Materials and methods
Design and participants
This was an observational, population-based study of patients 
aged 45 years or older who started LTOT for COPD in the 
Swedish Register for Respiratory Failure between October 1, 
2005 and June 30, 2009. The database was used in a recent 
safety study of opioids.16
Data sources
The Swedish Register for Respiratory Failure prospectively 
includes patients starting LTOT in Sweden with a nationwide 
coverage of approximately 85%.17 It contains physiological 
data including arterial blood gas tensions when breathing air 
and oxygen, body mass index, World Health Organization 
(WHO) performance status,18 and forced expiratory volume 
in 1 second registered at the start of LTOT. Details of the 
register have been published.19
Data on all dispensed outpatient prescriptions were 
obtained from the Swedish Prescribed Drugs Register20 
during the study period, which was from 91 days before the 
start of LTOT until the first of LTOT withdrawal, death, 
or study end (December 31, 2009). Drugs were catego-
rized according to the Anatomical Therapeutic Chemical 
Classification System (ATC codes) as previously described.16 
Vital status was obtained from the Swedish Causes of Death 
Register.
Opioid prescriptions
A random sample (n=2,000) of the cohort’s dispensed opioid 
prescriptions during the study period was derived from the 
database using the commando runiform in the statistical pack-
age Stata, version 13 (StataCorp LP; College Station, TX, 
USA). The random sample was analyzed in relation to medi-
cation type, dispensed quantity as WHO defined daily doses,21 
date of dispensing, and free-text indication. Each indication 
was reviewed by a respiratory physician and categorized as 
pain, breathlessness, other, or unknown (insufficient informa-
tion to identify an indication). Each prescription could have 
multiple indications and could include both a regular and an 
“as-needed” dose. In Sweden, the stated free-text indications 
are decided entirely by the prescribing physician and do not 
undergo external review by the pharmacy or clinic. Analy-
sis of primary interest was the period prevalence of opioid 
prescriptions during the follow-up period.
ethics
Participants provided their verbal consent when registered 
in Swedevox, and the consent procedure and the study were 
approved by the Lund University Research Ethics Committee 
(157/2007 and 350/2008), the Swedish National Board of 
Health and Welfare, and the Data Inspection Board.
statistical analyses
Baseline characteristics were summarized as counts and 
percentages for categorical variables, mean values with 
standard deviation or median with interquartile range (IQR) 
or range for normally and nonnormally distributed continu-
ous variables, respectively. Differences were tested using a 
t-test for continuous variables and chi-square test for unpaired 
categorical data. All tests were two sided, and statistical sig-
nificance was defined as P,0.05. Statistical analyses were 
conducted using Stata version 12.1 (StataCorp LP, College 
Station, TX, USA).
Results
Participants
A total of 2,249 COPD patients (59% women) were included 
prospectively and followed-up for a median 1.1 years (IQR 
0.6−2.0). During the study period, 1,034 patients (46 %) 
were dispensed at least one prescription of an opioid (in total 
13,722 dispensed opioid prescriptions). As shown in Table 1, 
patients who were prescribed opioids were aged 74±8 years, 
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were mostly women (66%), and 70% were mostly ambulatory 
with WHO status 1−2 at LTOT start. The random sample 
of 2,000 (15%) of the opioid prescriptions was dispensed 
by 575 patients.
Types of opioids
The most frequently prescribed opioids were tramadol (23%), 
oxycodone (23%), morphine (16%), and codeine (16%), as 
shown in Table 2. The average dispensed quantity was 9.3 
(IQR 3.7−16.7) defined daily doses per prescription. Of the 
opioid prescriptions, 417 (21%) included an as-needed dose 
(Table 2). No nebulized opioids were prescribed. The indica-
tion was present in 33% (n=662) of the opioid prescriptions 
and absent in 67% (n=1338) of the opioid prescriptions 
(Table 3). Characteristics were similar between the patients 
whose indications for opioids were known compared to those 
with unknown indications (Table 1).
Temporal patterns of indications
Table 3 shows indications for the prescriptions of opioids 
before and after the start of LTOT. The vast majority of the 
stated indications were pain (97%), with only 2% for breath-
lessness and 1% for other reasons among the prescriptions 
with known indications. Prescriptions with dual indications 
(pain and breathlessness) occurred in only 0.7% (n=5) of the 
known indications. During the last 6 months of the patients’ 
lives, the period prevalence of opioid prescriptions for breath-
lessness was only 4% (Table 4).
Opioids were prescribed predominantly among patients 
with WHO performance status 1−2 (Table 5).
Figure 1 shows the temporal pattern of opioid prescrip-
tions during follow-up by indication. Pain was the predomi-
nant indication throughout the study period. Breathlessness 
as an indication increased slightly during follow-up but the 
absolute numbers were low.
Discussion
Key findings
In oxygen-dependent COPD, breathlessness was an indica-
tion in less than 2% of opioid prescriptions and only 4% in 
the last 6 months of life. Among patients, 46% took an opioid 
during follow-up. Of the stated indications, the vast majority 
was pain (97%) and as many as 67% of opioid prescriptions 
lacked any information on the indication.
Table 1 Characteristics of oxygen-dependent COPD patients who were prescribed opioids
Characteristic Total  
(n=1,034)
Patients with known indication  
for prescription (n=273)
Patients with unknown indication 
for prescription (n=302)
age (years) 74.6±8 72.7±8 75.9±8
Females, n (%) 684 (66) 188 (69) 217 (72)
PaO2 air (kPa) 6.6±0.87 6.7±0.86 6.4±0.86
PaCO2 air (kPa) 6.3±1.2 6.3±1.1 6.4±1.2
WhO status, n (%)
0 49 (5) 17 (6) 11 (4)
1 379 (37) 114 (42) 84 (28)
2 344 (33) 85 (31) 110 (36)
3 145 (14) 22 (8) 56 (18)
4 20 (2) 1 (0) 8 (3)
FeV1 (l) 0.83±0.5 0.86±0.5 0.80±0.5
FeV1 (% of predicted) 34±17.3 34±17.9 33±15.4
Follow-up (days)a 442 (231–754) 568 (262–834) 545 (268–749)
Notes: Data presented as mean ± sD unless stated otherwise. n (%) of missing for PaO2, 146 (14); PaCO2, 151 (15); WhO status, 97 (9); FeV1, 403 (39); FeV1 (% of 
predicted), 453 (44). aMedian (first quartile–third quartile).
Abbreviations: FeV1, forced expiratory volume in 1 second; PaO2, arterial blood gas tension of oxygen on breathing air; PaCO2, arterial blood gas tension of carbon dioxide 
on breathing air; sD, standard deviation; WhO, World health Organization.
Table 2 Opioid prescriptions in oxygen-dependent COPD
Prescriptions Random sample
n=2,000
substance, n (%)
Codeine 318 (16)
Dextropropoxifen 270 (14)
Fentanyl 99 (5)
Morphine 314 (16)
Oxycodone 449 (22)
Tramadol 459 (23)
Others 91 (4)
DDDs per prescriptiona 9.3 (3.7–16.7)
Included “as-needed” dose, n (%) 417 (21)
Notes: a random sample of 2,000 (15%) of the total 13,722 opioid prescriptions 
was analyzed regarding medication type, dispensed amount, date of dispensation, 
and indication (free text). aMedian (first quartile–third quartile).
Abbreviation: DDDs, defined daily doses.
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strengths and limitations
Strengths of the present study include its national 
population-based design with complete longitudinal data 
on all dispensed outpatient opioid prescriptions and vital 
status nationwide. National registry data enabled complete 
follow-up in these frail patients with advanced disease. The 
use of a randomized prescription sample enabled analysis 
of the free-text indications, and the timing of prescription 
was analyzed in relation to LTOT and death.
A possible limitation was that a high proportion of pre-
scriptions lacked a stated indication. This would probably not 
lead to bias because the opioid indication is not externally 
reviewed and does not affect the price or the patient’s ability 
to dispense the opioid prescription in Sweden. It also reflects 
clinical reality and is an important finding in its own right 
by identifying an area of possible improvement in clinical 
practice. Clear information regarding the indication and 
aim of the treatment should be written on all prescriptions, 
especially regarding sick elderly patients and when informal 
caretakers are involved. Prescription data did not include 
opioids given in hospital, but this is unlikely to substantially 
change the relations between the treatment indications. 
Another possible limitation is that the study included data 
between 2005 and 2009. However, evidence that supported 
the use of opioids for the relief of breathlessness was already 
available from a Cochrane meta-analysis published in 200212 
and an adequately powered trial published in 2003.10 We 
did not have patient-reported data including breathlessness 
or quality of life scores to further characterize patients in 
this study.
Given the evidence of the efficacy of opioids for 
breathlessness,10,12,16,22 the study design, and the striking 
difference in prescribing for pain (97% of prescriptions) 
and breathlessness (2%), the finding that opioids are rarely 
used for refractory breathlessness in advanced and end-stage 
COPD likely has high validity.
relation to current evidence
Patients with advanced and oxygen-dependent COPD are 
known to suffer from high levels of breathlessness despite 
LTOT, both in outpatients and at the end of life.6–9 Opioids 
have been reported to be less prescribed near death in 
advanced COPD than in lung cancer, despite the presence of 
more breathlessness in COPD and similar rates of pain.6,14
The current findings are consistent with a Dutch study 
that chest physicians rarely prescribed opioids for refrac-
tory breathlessness to outpatients with advanced COPD.23 
The most frequent barriers to opioid prescription were the 
physician’s fear of possible serious adverse events, includ-
ing respiratory depression and resistance of some patients.23 
Although more research is needed, the evidence to date 
supports the safety of low-dose opioids for symptomatic 
treatment in advanced diseases including COPD. This 
evidence consists of a Cochrane meta-analysis,12 a system-
atic review,24 a randomized trial,10 and several studies.16,22 
Sustained-release morphine should be considered as a first 
line treatment and should be initiated at a low dose regu-
larly and titrated upward over days and weeks, balancing 
beneficial and adverse effects.25,26 All treatments assume 
adequate follow-up of the patient’s clinical condition and 
symptoms, including proper prophylaxis and treatment for 
expected effects such as opioid-related constipation.10,25 
Opioid side effects include initial nausea, worsened consti-
pation, or dizziness, which have been reversible upon dose 
reduction or discontinuation.16 There have been no reported 
serious adverse events related to titrated low-dose opioids, 
Table 3 Indications of 2,000 random opioid prescriptions among 575 patients with oxygen-dependent COPD
Indication, n (%) Overall 6 months  
before LTOT
First 6 months  
of LTOT
Last 6 months 
of LTOT
Known indication 662 (33) 153 (39) 188 (37) 215 (30)
Pain 642 (97) 150 (98) 183 (97) 206 (96)
Breathlessness 13 (2) 1 (0.7) 4 (2) 6 (3)
Other 7 (1) 2 (1) 1 (0.5) 3 (1)
Unknown indication 1,338 (67) 236 (61) 325 (63) 508 (70)
Note: Percentages might not sum to 100 because of rounding.
Abbreviation: lTOT, long-term oxygen therapy.
Table 4 Prescribed opioids at lTOT start versus before death in 
oxygen-dependent COPD patients who died (n=278)
Indication, n (%) First 6 months  
of LTOT
Last 6 months 
of life
Known indication 75 (28) 106 (29)
Pain 71 (95) 101 (95)
Breathlessness 3 (4) 4 (4)
Other 1 (1) 1 (1)
Unknown indication 191 (72)  265 (71)
Abbreviation: lTOT, long-term oxygen therapy.
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including no case of respiratory depression.12,16,22,24 A study 
using the present database found that low-dose opioids 
were not associated with increased rates of hospitalization 
or death in patients with severe oxygen-dependent COPD.16 
In a pharmacovigilance study of 83 patients who received 
10–30 mg oral morphine per day, no episodes of respiratory 
depression or hospitalizations were reported up to 3 months.22 
A recent meta-analysis (16 studies; 271 patients) reported that 
opioids safely improved breathlessness in severe COPD.24 
The findings from this meta-analysis are consistent with 
those of Jennings et al.12 Rocker et al reported that patients 
experienced beneficial effects from opioid therapy for breath-
lessness that sustained over months.27 The present study 
suggests that, despite the high symptom burden6 and the 
available safety data,12,16,22,24 there is a widespread reluctance 
to prescribe opioids for breathlessness in advanced COPD.
What this study adds
This is, to the authors’ knowledge, the first study looking at 
the indications for prescribing opioids in severe COPD. This 
study shows that patients with oxygen-dependent COPD are 
treated with opioids; 46% of patients were dispensed at least 
one prescription during follow-up. Pain was the dominating 
opioid indication (97%), and breathlessness was the indica-
tion in only 2% of the prescriptions. Although breathlessness 
as an indication increased, slightly during follow-up, absolute 
numbers were low and during the last 6 months of life, only 
4% of opioid prescriptions were for breathlessness. These 
findings further support undertreatment of breathlessness 
both for symptom relief and at the end of life.6
Implications and the future
This study forms a crucial baseline against which to evalu-
ate temporal trends in opioid prescribing for COPD as the 
evidence base continues to evolve. Research is needed to 
inform and implement evidence-based opioid treatment 
for the relief of refractory breathlessness in severe COPD. 
Large-scale longitudinal studies are needed to evaluate 
adverse effects and the net clinical benefit of opioids in 
clinical practice.16,28 Initiatives for implementing evidence-
based treatment for symptom relief are warranted in severe 
respiratory diseases.
For clinicians, this study identifies potential improve-
ment opportunities in the management of chronic refractory 
breathlessness. Changing the threshold at which people 
experience breathlessness is likely to have important impli-
cations for activities of daily living. It is likely that people 
exert themselves to the same level of breathlessness, and 
if this takes longer or more intense exertion to reach, then 
people are likely to be more active, therefore breaking 
the cycle of deconditioning. Structured measurement of 
Table 5 Indications of opioid prescriptions by WhO performance status in oxygen-dependent COPD
Indication, n (%) WHO status 0 WHO status 1 WHO status 2 WHO status 3 WHO status 4
Known indication 38 (45) 273 (42) 224 (32) 55 (17) 2 (7)
Pain 38 (100) 269 (99) 211 (94) 53 (96) 2 (100)
Breathlessness 0 2 (0.7) 8 (4) 2 (4) 0
Other 0 2 (0.7) 5 (2) 0 0
Unknown indication 47 (55) 374 (58) 485 (68) 275 (83) 28 (93)
Notes: Percentages might not sum to 100 because of rounding. WhO status: 0, fully active, able to carry out all pre-disease activities without restriction; 1, restricted in 
physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work, office work; 2, ambulatory and capable of all 
selfcare but unable to carry out any work activities, and up and about more than 50% of waking hours; 3, capable of only limited selfcare, confined to bed or chair more than 
50% of waking hours; 4, completely disabled, incapable of any selfcare, totally confined to bed or chair.
Abbreviation: WhO, World health Organization.
    
 
447LPHSHULRGLQUHODWLRQWR/72744±WR
     









2WKHU%UHDWKOHVVQHVV3DLQ

Figure 1 Trend for stated indications of opioid prescriptions in 575 patients with 
oxygen-dependent COPD.
Notes: Percentage of dispensed opioid prescriptions with the indication for pain, 
breathlessness, or other (of the prescriptions with known indication; n=662; 33%). 
Time periods are 3 months before starting lTOT (-3 to 0 months), and each 
quartile (Q1–Q4) of follow-up during LTOT.
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the breathlessness severity in routine care is important 
in evidence-based symptomatic treatment.29 Given their 
growing evidence of efficacy and safety, low-dose opioids, 
after careful initiation and titration, can be prescribed with 
better confidence for the relief of refractory breathlessness 
in advanced COPD.30,31 Another important finding is that 
more than half of the opioid prescriptions lacked any written 
indication. Clear oral and written information on why opioid 
is given and on the aim of the therapy is likely important for 
the safety of the therapy, compliance, and symptom control 
in these often elderly, frail, and often multi-morbid patients 
with end-stage respiratory diseases.
Conclusion
In severe oxygen-dependent COPD, almost half of patients 
were treated with opioids at some point, largely for pain 
(97%). Breathlessness was a rare indication for opioids (2%), 
even near death.
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